Protease Inhibitor Vs. Raltegravir-based ART and Inflammation in HIV Infection

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 20, 2017

Primary Completion Date

March 31, 2021

Study Completion Date

March 31, 2021

Conditions

HIV

Interventions

DRUG

Integrase Inhibitor

Raltegravir

Trial Locations (1)

Chronic Viral Illness Service, McGill University Health Centre, Montreal

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

McGill University Health Centre/Research Institute of the McGill University Health Centre

OTHER

NCT02691065 - Protease Inhibitor Vs. Raltegravir-based ART and Inflammation in HIV Infection | Biotech Hunter | Biotech Hunter